Adaptimmune Therapeutics Plc has appointed Gavin Wood as chief financial officer, effective 1 April, as it prepares to commercialise its first immunotherapy for cancer in 2022. Mr Wood most recently served as CFO and a director of Abcam Plc and before that, as an executive at Affymetrix Inc, a company that was acquired by ThermoFisher Scientific Inc in 2016. Mr Wood is a chartered accountant and holds a bachelor of arts degree in archaeology from the University of Durham, UK.
Adaptimmune announced the appointment on 18 February 2020.
Copyright 2020 Evernow Publishing Ltd